Clinical trials: Cerebrovascular Event
Carotid Artery Stenosis, Cerebral Infarction
Bacteria in Atherosclerotic Plaques and Adverse Events
This study is a prospective, multicenter cohort study conducted in western China. The registry study is primarily conducted at the Department of Neurosurgery, Tangdu Hospital, with participation from the Departments of…
- Conditions
- Carotid Artery Stenosis, Cerebral Infarction, Diabetes, Bacteria
- Trial name
- NCT06935279
- Testing
- Carotid Endarterectomy
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Tang-Du Hospital
Heart Failure, Coronary Artery Disease
A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure
The purpose of this study is to assess the effectiveness and safety of rivaroxaban compared with placebo (inactive medication), in reducing the risk of death, myocardial infarction or stroke in participants with heart failure and…
- Trial name
- COMMANDER HF (NCT01877915)
- Testing
- Rivaroxaban, Standard of care for heart failure and coronary artery disease
- Where
- 562 sites in United States, Argentina and 30 more
- Volunteers
- 5,081 people
- Sponsor
- Janssen Research & Development, LLC
Cardiovascular Disease
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
This study evaluates the PCSK9 inhibitor, Bococizumab (PF-04950615;RN316), compared to placebo, in reducing the occurrence of major cardiovascular events, including cardiovascular death, myocardial infarction, stroke, and…
- Trial name
- SPIRE-1 (NCT01975376)
- Testing
- bococizumab (PF-04950615)
- Where
- 1,745 sites in United States, Argentina and 34 more
- Volunteers
- 16,784 people
- Sponsor
- Pfizer
Acute Ischaemic Stroke, Transient Ischaemic Attack
[SOCRATES -Acute Stroke Or Transient IsChaemic Attack TReated With Aspirin or Ticagrelor and Patient OutcomES]
The primary objective of the study is to compare the effect of 90-day treatment with ticagrelor (180 mg [two 90 mg tablets] loading dose on Day 1 followed by 90 mg twice daily maintenance dose for the remainder of the study) vs…
- Trial name
- SOCRATES (NCT01994720)
- Testing
- ticagrelor, Acetylsalicylic acid (ASA)
- Where
- 521 sites in United States, Argentina and 31 more
- Volunteers
- 13,307 people
- Sponsor
- AstraZeneca
Atherosclerosis, Ischemia
Trial to Assess the Effects of Vorapaxar (SCH 530348; MK-5348) in Preventing Heart Attack and Stroke in Patients With Atherosclerosis (TRA 2°P - TIMI 50) (P04737)
The study is designed to determine whether vorapaxar, when added to the existing standard of care (SOC) for preventing heart attack and stroke (eg, aspirin, clopidogrel) in participants with a known history of atherosclerosis…
- Conditions
- Atherosclerosis, Ischemia, Myocardial Infarction, Cerebrovascular Accident
- Trial name
- NCT00526474
- Testing
- Vorapaxar
- Volunteers
- 26,449 people
- Sponsor
- Merck Sharp & Dohme LLC
Postoperative Complications, Memory Disorders
A Study to Determine if Carbon Dioxide Lavage During Total Knee Surgery Reduces Intraoperative Embolic Events
The purpose of this study is to determine if the use of a carbon dioxide lavage device (CarboJet) to clean bone surfaces during total knee surgery decreases intraoperative embolic events when compared with standard orthopedic…
- Trial name
- NCT00736125
- Testing
- pulsatile saline lavage, carbon dioxide lavage
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Kinamed Incorporated
Thromboembolism, Hemolysis
Lavare Cycle in Patients Receiving HeartWare Left Ventricular Assist Device
Left ventricular assist device (LVAD) patients remain at risk for pump thrombus and thromboembolic events through multiple mechanisms.
- Conditions
- Thromboembolism, Hemolysis, Stroke
- Trial name
- NCT04199793
- Testing
- Lavare On, Lavare Off
- Where
- 4 sites in United States
- Volunteers
- 9 people
- Sponsor
- Vanderbilt University Medical Center
Cardiovascular Diseases, Heart Diseases
Niacin Plus Statin to Prevent Vascular Events
The purpose of this study is to determine whether raising "good cholesterol" with a drug based on the vitamin niacin, while lowering "bad cholesterol" with a statin drug, can prevent more heart disease than the statin alone.
- Conditions
- Cardiovascular Diseases, Heart Diseases, Cerebrovascular Accident, Coronary Disease
- Trial name
- NCT00120289
- Testing
- Extended release niacin, Simvastatin
- Where
- 91 sites in United States, Canada
- Volunteers
- 3,414 people
- Sponsor
- Axio Research. LLC
Myocardial Infarction, Cardiovascular Death
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
This study is being carried out to see if a new drug called ticagrelor given twice daily in addition to the ASA therapy decreases the frequency of cardiovascular events (e.g., death from heart disease, heart attack, or stroke).
- Conditions
- Myocardial Infarction, Cardiovascular Death, Atherothrombosis, Stroke
- Trial name
- PEGASUS (NCT01225562)
- Testing
- Ticagrelor 90 mg, Ticagrelor 60 mg
- Where
- 826 sites in United States, Argentina and 29 more
- Volunteers
- 21,379 people
- Sponsor
- AstraZeneca
Systemic Arterial Hypertension, Hypertension Resistant to Conventional Therapy
Renin-angiotensin-aldosterone System Polymorphisms in Resistant Hypertension and Adverse Cardiovascular Events
Renin-angiotensin-aldosterone system (RAAS) polymorphisms influence 24h arterial pressure fluctuation. Resistant systemic arterial hypertension (RSAH) has an increased risk of end organ damage and unfavourable prognosis, whereas…
- Conditions
- Systemic Arterial Hypertension, Hypertension Resistant to Conventional Therapy, Myocardial Infarction, Stroke
- Trial name
- GENHART (NCT01173029)
- Testing
- Anti-hypertensive drug treatment
- Where
- Brazil
- Volunteers
- 92 people
- Sponsor
- Universidade Gama Filho
Atrial Fibrillation (AF), Stroke
Safety and Tolerability of Abelacimab (MAA868) vs. Rivaroxaban in Patients With Atrial Fibrillation
The purpose of the ANT-006 study is to evaluate the bleeding profile of abelacimab relative to rivaroxaban in patients with atrial fibrillation (AF) at moderate-to-high risk of stroke.
- Trial name
- AZALEA-TIMI 71 (NCT04755283)
- Testing
- Abelacimab, Rivaroxaban
- Where
- 92 sites in United States, Canada and 5 more
- Volunteers
- 1,287 people
- Sponsor
- Anthos Therapeutics, Inc.
Myocardial Infarction, Stroke
Women's Health Initiative Strong and Healthy Study
The WHISH trial applies state-of-the science behavioral principles and currently available technologies to deliver a physical activity intervention without face-to-face contact to ~25,000 older U.S. women expected to consent.
- Conditions
- Myocardial Infarction, Stroke, Cardiovascular Mortality, Hip Fractures
- Trial name
- WHISH (NCT02425345)
- Testing
- Physical Activity
- Volunteers
- 49,331 people, healthy volunteers welcome
- Sponsor
- Fred Hutchinson Cancer Center
Cardiovascular Disease, Peripheral Arterial Disease
Treatment of HDL to Reduce the Incidence of Vascular Events HPS2-THRIVE
The primary aim is to assess the effects of raising HDL cholesterol (the good type) with extended release niacin/laropiprant 2g (previously known as MK-0524A) versus matching placebo on the risk of heart attack or coronary death…
- Conditions
- Cardiovascular Disease, Peripheral Arterial Disease, Diabetes Mellitus, Coronary Heart Disease
- Trial name
- HPS2-THRIVE (NCT00461630)
- Testing
- ER niacin/laropiprant, simvastatin, ezetimibe/simvastatin
- Where
- United Kingdom
- Volunteers
- 25,673 people
- Sponsor
- University of Oxford
Acute Ischemic Stroke
Imaging Guided Patient Selection for Interventional Revascularization Therapy
The primary objective of this clinical evaluation is to determine the safety and effectiveness of the Penumbra System in a stroke cohort who presents within 8 hours from symptom and with a known core infarct volume at admission.
- Trial name
- START (NCT00963989)
- Testing
- Penumbra System
- Where
- United States
- Volunteers
- 146 people
- Sponsor
- Penumbra Inc.